|Bid||2.2000 x 2200|
|Ask||2.2400 x 4000|
|Day's range||2.1900 - 2.3400|
|52-week range||2.0400 - 10.2700|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||11 Aug 2021 - 16 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.75|
The company’s Preecludia™ test performed strongly in a broad, intended-use populationSAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™ rule-out test for preeclampsia and achievement of the primary endpoint of the study protocol. The PRO-104 clinical validation study was a prospective, multi-center, observational study with over 1,300 enrolled subjects.
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi’s medical device experience and her focus on development of strategic partnerships will prove valuable as the company advances its innovation pipeline. “As part of our strategic transformation, we are sharpening our focus on efforts to develop the drug discovery and delivery systems
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Progenity, Inc. (NasdaqGM: PROG).